Agonist News and Research

RSS

GLP-1 treatments may reduce knee replacement surgery rates

GLP-1 receptor agonist drugs, used for the treatment of diabetes, and more recently, weight loss, are associated with a significantly lower long term risk of knee replacement surgery as a result of osteoarthritis, finds an analysis of medical records data, published in the open access journal Regional Anesthesia & Pain Medicine.

2 Jun 2026

GLP-1 therapy linked to slower biological aging processes

Glucagon-like peptide-1 (GLP-1) receptor agonist medications have gained widespread attention for effectively treating obesity, lowering blood sugar and decreasing the risk of cardiovascular disease.

2 Jun 2026

Existing drug mitigates muscle loss from GLP-1 medications

Millions of Americans are currently taking GLP-1 medications such as Ozempic or Wegovy for weight loss.

2 Jun 2026

Scientists rethink GLP-1 delivery to improve dosing, tolerability, and adherence

The review highlights nanocarriers, microspheres, hydrogels, microneedles, long-acting formulations, and co-formulations as promising but mostly early-stage strategies that still require stronger long-term clinical evidence.

27 May 2026

Vaginal bromocriptine may ease pain and heavy bleeding in adenomyosis

A pilot randomized controlled trial found that vaginal bromocriptine reduced menstrual bleeding, pelvic pain, menstrual duration, and cycle irregularity in women with adenomyosis compared with routine treatment.

27 May 2026

Retatrutide reshapes metabolism in obesity and type 2 diabetes, study finds

Retatrutide altered circulating metabolites and lipids linked to fatty acid oxidation and insulin resistance in people with obesity, with or without type 2 diabetes. These biomarker changes suggest improved metabolic health, but the post-hoc analysis remains hypothesis-generating and does not prove direct clinical benefit.

26 May 2026

New study tests vitamin D analog against pancreatic cancer

A small clinical trial led by Dana-Farber Cancer Institute researchers put a Salk Institute idea to the test in patients: that activating the vitamin D receptor can help reshape the protective environment surrounding pancreatic tumors in ways that could make the notoriously difficult-to-treat cancer more vulnerable to therapeutic treatments.

26 May 2026

Oral drug improves platelet recovery during chemotherapy in gastrointestinal cancer patients

An oral medication already approved for thrombocytopenia in patients with liver disease significantly improved platelet recovery and helped patients with gastrointestinal cancers maintain platelet counts needed to continue chemotherapy as scheduled, according to results from a phase 2 clinical trial led by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and Mass General Hospital.

21 May 2026

Gut-localized drug avoids systemic safety risks while reversing hormonal imbalances in mice

Polycystic ovary syndrome (PCOS) is one of the most common hormonal disorders in women of reproductive age. It can cause irregular periods, infertility, weight gain, insulin resistance, and elevated male hormone levels. Current treatments mainly focus on managing symptoms rather than addressing underlying causes.

20 May 2026

Methylene blue enhances hair follicle stem cell regeneration under stress

A new research paper was published in Volume 18 of Aging-US on May 5, 2026, titled "Methylene blue protects hair follicle stem cells from oxidative and metabolic stress to enhance hair regeneration."

19 May 2026

New therapies could help type 1 diabetes care move beyond insulin alone

Disease-modifying therapies for type 1 diabetes are beginning to move care beyond insulin replacement by targeting immune dysregulation, beta-cell stress, and preservation of endogenous beta-cell function. Teplizumab marks a major clinical milestone, but the review emphasizes that durable metabolic remission will likely require earlier screening, better patient selection, and sequential or combination therapies.

18 May 2026

Endoscopic sleeve gastroplasty outperforms oral semaglutide in short-term weight loss

A comparative study, presented at ESGE Days 2026, has found that endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide in adults with obesity.

15 May 2026

New obesity medications offer a potent tool for combating hypertension

A meta-analysis of 32 studies and 43,618 adults presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows that use of new classes of obesity drugs for weight loss is associated with a clinically relevant drop in blood pressure (BP): a 0.34 mmHg reduction in systolic BP per 1\% weight loss.

15 May 2026

Turning the flu virus into a powerful tool to fight cancer

A recent Views & Comments article published in Engineering highlights advances in repurposing influenza viruses as flexible therapeutic platforms for infectious diseases and cancer, driven by progress in reverse genetics and viral vector engineering.

14 May 2026

Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide therapy. The phase 3b ATTAIN-MAINTAIN trial suggests switching to once-daily oral therapy may help reduce weight regain when injectable treatment is discontinued.

13 May 2026

Adding GLP-1 drugs to behavioral interventions silences food noise

New research presented at this year's European Congress on Obesity in Istanbul, Turkey, shows that use of obesity drugs alongside behavioral interventions leads to a larger drop in so called 'food noise' than in those using the behavioral therapy alone.

13 May 2026

Could GLP-1 drugs help breast cancer patients live longer?

A large retrospective cohort study of adult female breast cancer patients found that GLP-1 receptor agonist use was associated with better all-cause survival and recurrence-free survival in patients with obesity or type 2 diabetes. The strongest associations were seen versus non-use in obesity and versus insulin or metformin in type 2 diabetes, while comparisons with SGLT2 inhibitors were less consistent and require further study.

12 May 2026

Daily orforglipron treatment reduces weight and blood sugar in seniors

A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.

11 May 2026

Asthma medication formoterol shows promise for treating fatty liver disease

MUSC researchers are tackling MASH, or metabolic dysfunction-associated steatohepatitis, a liver disease affecting hundreds of millions worldwide.

8 May 2026

Opioid overdose survivors face elevated mortality risk within one year

After an emergency department visit for an opioid overdose, 9 per cent of individuals died and 21 per cent experienced a repeat opioid overdose in the following year, according to a new study from ICES and the Centre for Addiction and Mental Health (CAMH).

7 May 2026